Image source: Canva
B-cell lymphoma is a cancer of certain white blood cells called lymphocytes. The disease can cause enlargement of the lymph nodes, leading to pain and discomfort. Swollen lymph nodes can also compress and disrupt the function of other nearby organs in the body. A clinical trial led by Mark Roschewski, M.D., Senior Clinician in the Lymphoid Malignancies Branch, is researching a novel immunotherapy approach for indolent b-cell lymphoma, which is associated with frequent disease relapse. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the NCI Medical Oncology Referral Office at (240) 760-6050, or ncimo_referrals@nih.gov.
Clinicaltrials.gov identifier: NCT04599634
NCI Protocol ID: NCI-20-C-0162
Official Title: A Phase 1 Study of Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.